The rhPSMA-7 imaging compound is capable of targeting and labeling prostate cancer cells in conjunction with either PET imaging radiopharmaceuticals such as Blue Earth's Axumin (fluciclovine F-18) or therapeutic radioisotopes such as lutetium-177 (Lu-177), according to the company. This potentially allows for rhPSMA-7 to facilitate both imaging and therapy for prostate cancer.

Blue Earth plans to continue developing rhPSMA-7 and to collaborate with Scintomics on optimizing its therapeutic applications for prostate cancer therapy.